San Diego, United States
ABM Therapeutics is carving a niche in the biopharma sector with its focus on novel drug discovery aimed at treating brain cancers and metastases, a critical unmet need in oncology. Established in 2015 by a seasoned team of biotech and pharmaceutical experts from North America, the company has developed a robust proprietary pipeline to transform the landscape of brain medicine research and development.
The company's flagship drug candidate, ABM-1310, is a cutting-edge BRAF inhibitor designed for optimal cell permeability and brain penetration, targeting cancers manifesting the BRAFV600 mutation. Having secured IND approval in both the USA and China, it stands as a potential best-in-class therapeutic option.
In its most recent financing round, ABM Therapeutics attracted a $30.00M Series B investment from prominent investors including Viva BioInnovator and Baidu Venture, a testament to its promising innovation and strategic direction within the pharmaceutical industry.
